Latest news
Drug Delivery and Supply Chain
PacBio and Verily Health announce multi-year strategic collaboration to scale long-read genomics for biomedical AI
PacBio, a developer of advanced sequencing technologies, and Verily Health, a healthcare data intelligence company, have announced a multi-year strategic collaboration to integrate PacBio HiFi...
Clinical Trials Insights
Rapport Therapeutics announces positive topline results from its phase 2 trial of RAP-219 for the treatment of bipolar mania
Rapport Therapeutics, a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders,...
Drug Delivery and Supply Chain
ScionxBio announces collaboration to develop long-acting xRNA therapeutics
ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA...
Clinical Trials Insights
Dr Elizabeth Rohrs of the Royal Columbian Hospital reports a 39% reduction in ICU pneumonia rates among patients treated with nasal photodisinfection at ESICM
Dr Elizabeth Rohrs PhD, RRT, principal investigator at Royal Columbian Hospital (RCH) and RCH Foundation Research Director, recently presented findings from the SMURF (Suppression...
Drug Delivery and Supply Chain
Armenia grants first marketing authorisations for Agenus’ BOT+BAL in previously treated MSS metastatic colorectal cancer
The Ministry of Health of the Republic of Armenia has granted marketing authorisations for Agenus’ Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use...
Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility...
Finance, mergers and appointments
Bolt Biotherapeutics announces acquisition of Prana Therapies and US$120 million concurrent private placement to advance PRA-216 in multiple high-value inflammatory indications
Bolt Biotherapeutics has acquired Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multi-specific antibodies designed to deliver best-in-disease therapies
Following the acquisition, the company...
Clinical Trials Insights
Muna Therapeutics announces positive phase 1 results supporting potential of oral small-molecule TREM2 modulator, MNA-001, in Alzheimer’s disease
Muna Therapeutics (Muna), a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, has announced positive results from its phase 1 study of MNA-001,...
Clinical Trials Insights
Cancer research group have entered into phase 2/3 clinical trial collaboration to evaluate ivonescimab in first-line biliary tract cancer
Akeso has announced that Summit Therapeutics, its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group...
Clinical Trials Insights
Geneos Therapeutics initiates phase 2 randomised clinical trial evaluating neoantigen-targeted personalised DNA immunotherapy for cancer
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalised immunotherapy for cancer (PIC), has announced the initiation of its...
Clinical Trials Insights
Paradigm Therapeutics announces first patient enrolled in phase 3 trial for Zorblesia in epidermolysis bullosa
Paradigm Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare diseases, has announced that the first patient has been enrolled in...
Merck, a leading science and technology company, has signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business within its...
Clinical Trials Insights
Geneos Therapeutics initiates phase 2 randomised clinical trial evaluating neoantigen-targeted personalised DNA immunotherapy for cancer
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalised immunotherapy for cancer (PIC), has initiated a phase 2 randomised...
Drug Discovery & Development
FDA authorises Lynch Regenerative Medicine’s IND for a phase 2b clinical trial for injection of rhPDGF-BB for treatment of infraorbital hollowing
An Investigational New Drug (IND) application for Lynch Regenerative Medicine's phase 2 clinical trial evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in adults...
Drug Delivery and Supply Chain
Rznomics granted orphan medicinal product designation for RZ-001 for the treatment of glioma by the European Commission
Rznomics Inc, a biopharmaceutical company specialising in the development of RNA-based gene therapies, announced that the European Commission (EC) has granted orphan medicinal product...
Finance, mergers and appointments
P95 Julius Clinical becomes Akeura, a specialist CRO in clinical development and real-world evidence
P95 Julius Clinical has become Akeura, a global specialist contract research organisation (CRO) with dual expertise in clinical and real-world settings. The launch of...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
MOST POPULAR POSTS
© 2026 Pharma Press Global.